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UV radiation induces systemic immunosuppression. Because non-
steroidal anti-inﬂammatory drugs suppress UV-induced immuno-
suppression, prostanoids have been suspected as a crucial mediator
of this UV effect. However, the identity of the prostanoid involved
and itsmechanismofaction remainunclear.Here,weaddressed this
issue by subjecting mice deﬁcient in each prostanoid receptor
individually or mice treated with a subtype-speciﬁc antagonist to
UV irradiation. Mice treatedwith an antagonist for prostaglandin E
receptor subtype 4 (EP4), but not those deﬁcient in other prostanoid
receptors, show impairedUV-induced immunosuppression,whereas
administration of an EP4 agonist rescues the impairment of the
UV-induced immunosuppression in indomethacin-treatedmice. The
EP4 antagonist treatment suppresses an increase in the number of
CD4+/forkhead box P3-positive (Foxp3+) regulatory T cells (Treg
cells) in theperipheral lymphnodes (LNs) anddendritic cells express-
ingDEC205 in theLNsand theskinafterUV irradiation. Furthermore,
the EP4 antagonist treatment down-regulates UV-induced expres-
sion of receptor activator of NF-κB ligand (RANKL) in skin keratino-
cytes. Finally, administration of anti-RANKL antibody abolishes the
restoration of UV-induced immunosuppression by EP4 agonism in
indomethacin-treated mice. Thus, prostaglandin E2 (PGE2)–EP4 sig-
naling mediates UV-induced immunosuppression by elevating the
number of Treg cells through regulation of RANKL expression in
the epidermis.
It has been known for more than 3 decades that UV radiation inthe UVB (280–320 nm) range induces immunosuppression in
animals. Fisher and Kripke (1) ﬁrst noticed that UV-irradiated
mice were more susceptible to transplanted cancer than non-
irradiatedmice and that lymphoid cells from irradiatedmice failed
to eliminate cancer cells. Based on these ﬁndings, they suggested
that UV radiation induces systemic immunosuppression in ani-
mals and that this immunosuppression contributes indirectly to
causing skin cancer. Systemic immunosuppression induced by UV
was conﬁrmed later in several animal models including contact
hypersensitivity (CHS) (2), delayed-type hypersensitivity (3), al-
lergic asthma (4), and experimental autoimmune encephalomy-
elitis (EAE) (5). This immunosuppressive effect also is exploited
clinically, and UV radiation is used to treat a variety of diseases,
such as psoriasis, vitiligo, and atopic dermatitis (6).
Several immune modulatory factors and immune cells are
implicated in UV-induced systemic immunosuppression, in-
cluding TNF-α, IL-4, IL-10 (7), platelet-activating factor (8),
histamine (9), cis-urocanic acid (10), and natural-killer T cells
(NKT cells) (11). In the early 1980s, T lymphocytes were found
to play an important role in UV-induced systemic immunosup-
pression (12). Quite recently, regulatory T cells (Treg cells) were
implicated in UV-induced systemic immunosuppression (13, 14).
Loser et al. (13) reported that epidermal receptor activator for
NFκB ligand (RANKL) is associated with UV-induced Treg cells
and immunosuppression. They suggested that UV exposure up-
regulates RANKL expression in keratinocytes, leading to the
induction of Treg cells through activating epidermal dendritic
cells (DCs) expressing DEC205, which recently were conﬁrmed
to be specialized to induce forkhead box P3-positive (Foxp3+)
Treg cells (15). However, deﬁnite proof of the involvement of
RANKL and Treg cells in UV-induced systemic immunosup-
pression has yet to be obtained.
Among the factors involved in UV-induced immunosuppres-
sion are prostanoids. Prostanoids, comprising prostaglandin (PG)
E2, PGD2, PGF2α, PGI2, and thromboxane (TX) A2, are oxy-
genated metabolites of arachidonic acid produced by sequential
catalysis of cyclooxygenase (COX) and respective synthases.
They are produced in large amounts in inﬂammatory sites in
response to various stimuli, including UV, and exert a variety of
physiological and pathophysiological actions by acting on G
protein-coupled receptors that includes four subtypes of PGE
receptor (EP1, EP2, EP3, and EP4), PGD receptors (DP1 and
DP2), PGF receptor (FP), PGI receptor (IP) and TXA receptor
(TP) (16). Implication of prostanoids in UV irradiation-induced
immunosuppression has been indicated by many studies showing
that nonsteroidal anti-inﬂammatory drugs (NSAIDs), including
indomethacin, that exert their effect through COX inhibition can
reverse the immunosuppressive effect of UV radiation (8, 9, 17).
Combined with the fact that prostanoids such as PGE2 are
produced abundantly by keratinocytes upon UV exposure (18,
19), this reversal strongly suggests that prostanoids are involved
in UV-induced immunosuppression. However, the identity of
the prostanoid involved and how it is related to other proposed
mechanisms of UV-induced immunosuppression remain un-
known. We combined genetic and pharmacological approaches
and addressed this long-standing question on the role of pros-
tanoids in UV-induced systemic immunosuppression.
Results
UV Irradiation Induces Systemic Immunosuppression and Increases
the Number of Treg Cells Responsible for UV-Induced Systemic
Immunosuppression. UV-induced systemic immunosuppression
usually is examined in mice by CHS response. We adopted a
protocol of previous studies (7, 9) with some modiﬁcations (Fig.
1A). We shaved the back skin of C57BL/6 mice on day 0, irra-
diated them on the back with UV on day 1, sensitized them on
the abdomen with 2,4-dinitroﬂuorobenzene (DNFB) on day 5,
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challenged them on the ear on day 10, and evaluated ear swelling
on day 11. We ﬁrst determined an optimal UV dose producing
effective systemic immunosuppression by applying various doses
of UV. UV doses more than 5 kJ/m2 showed effective immu-
nosuppression as evidenced by signiﬁcantly lower CHS responses
in these groups of mice than in nonirradiated control mice (Fig.
1B). Although the skin was severely injured in mice irradiated
with UV at more than 7 kJ/m2, irradiation at 5 kJ/m2 caused only
slight erythema on the skin. We therefore used 5 kJ/m2 of UV in
our subsequent study. The immunosuppression induced by this
dose of UV lasted for at least 2 wk (Fig. S1). To conﬁrm the
immunosuppression at the cellular level, we collected regional
lymph nodes (LNs) on day 10 and cultured LN cells in the
presence of 2,4-dinitrobenzene sulfonic acid (DNBS), a water-
soluble form of DNFB. Consistent with the CHS response being
driven mainly by IFN-γ–producing T cells, the cells from the UV-
irradiated mice showed signiﬁcantly lower cell proliferation and
signiﬁcantly less IFN-γ production than cells from nonirradiated
mice (Fig. 1 C and D). Because it has been suggested that Treg
cells play a prominent role in the immunosuppressive effect of
UV (14), we monitored the number of Treg cells in the LNs after
UV irradiation. The number of CD4+Foxp3+ Treg cells (20) in-
creased in a time-dependent manner and reached a signiﬁcant
increase 3 d after UV irradiation (Fig. 1E), a result that is in
agreement with our ﬁnding in CHS (Fig. S1) and with a previous
report that systemic immunosuppression in mice starts not ear-
lier than 3 d after the irradiation (21). We then assessed the
signiﬁcance of Treg cells in UV-induced systemic immunosup-
pression by using Foxp3hCD2/hCD52 mice. This line of mice
expresses human CD2 and human CD52 chimeric protein in
Foxp3+ Treg cells (22). As reported, Treg cells in these mice, but
not in wild-type mice, were markedly depleted using Mabcam-
path, an anti-human CD52 antibody (Fig. S2). Treg-depleted
Foxp3hCD2/hCD52 mice irradiated with UV showed signiﬁcantly
higher CHS response than UV-irradiated wild-type mice (Fig.
1F). This result thus shows that Treg cells are required for UV-
induced systemic immunosuppression.
PGE2–EP4 Receptor Signaling Mediates UV-Induced Systemic Immu-
nosuppression. Using the system deﬁned above, we next examined
involvement of COX and PGs in UV-induced immunosuppression
in our system. COX-2, but not COX-1, was strongly induced in skin
keratinocytes of mice by UV irradiation (Fig. S3 A and B).
Quantitative analysis of arachidonate metabolites revealed that, in
comparison with other PGs, PGE2 was produced substantially in
the skin 24 h after UV irradiation, and its production was sup-
pressed signiﬁcantly by indomethacin treatment (Fig. S3C). We
then treated mice with 4 mg kg−1 d−1 indomethacin added in
drinking water for 3 d beginning 24 h before UV irradiation.
Treatment with indomethacin alone did not affect the CHS re-
sponse. However, in agreement with previous studies (8, 9, 17),
the indomethacin treatment reversed the UV-induced immuno-
suppression, as shown by signiﬁcantly higher CHS response in the
treated mice than in the control UV-irradiated mice (Fig. 2A).
Similarly, treatment with a selective COX-2 inhibitor, SC-236,
but not with a selective COX-1 inhibitor, SC-560, reversed the UV-
induced immunosuppression (Fig. S4). Because these results sug-
gest the involvement of PG in our experiment, we subjected mice
deﬁcient in each PG receptor individually (23) to our UV-induced
systemic immunosuppression model. We excluded EP4-deﬁcient
mice from the experiment because they have a mixed genetic
background of 129/Ola and C57BL/6 and show impaired CHS
response (24). Instead we used an EP4 antagonist, ONO-AE-3–
208 (24), and administered it to wild-type C57BL/6 mice to block
the EP4 receptor pharmacologically. We also administered a TP/
DP2 antagonist, ramatroban (25), to TP-deﬁcient mice to examine
involvement of DP2. We noted that UV irradiation induced im-
munosuppression in mice lacking DP1, EP1, EP2, EP3, FP, IP, or
TP and in TP-deﬁcient mice treated with ramatroban to a level
similar to that found in controls (Fig. 2B), suggesting that these
PG receptors do not play a crucial role in the induction of the
systemic immunosuppression by UV exposure. To examine the
involvement of EP4 receptor signaling, various doses of the EP4
antagonist were applied to wild-type mice in drinking water for the
same period as described for indomethacin treatment. Notably,
administration of the EP4 antagonist at 50 mg kg−1 d−1 and 100 mg
kg−1 d−1 signiﬁcantly prevented the UV-induced immunosup-
pression (Fig. 2C). The EP4 antagonist treatment restored the
CHS response to a level found in mice treated with indomethacin
or SC-236 (Fig. S4). Histological examination of the ear 24 h
after the challenge showed that UV irradiation considerably de-
creased cell inﬁltration and edema in the dermis and that these
Fig. 1. UV irradiation suppresses CHS responses in
mice and induces Treg cells in draining LNs. (A) The
experimental protocol. Mouse back skin is shaved
on day 0, subjected to UV or sham irradiation (No
UV) on the back on day 1, sensitized with 0.5%
DNFB applied to the shaved abdomen on day 5, and
challenged by applying 0.2% DNFB on the ear. Ear
swelling is evaluated 24 h after the challenge. (B)
Dose-dependent suppressive effect of UV on CHS
responses. Ear swelling was measured 24 h after
challenge in sham-irradiated mice (No UV) and mice
irradiated with indicated doses of UV (n = 4 mice per
group). (C) Reduced DNBS-induced proliferation of
LN cells from UV-irradiated mice. Cells were pre-
pared from draining LNs of sham-irradiated mice
(No UV) or mice irratiated with 5 kJ/m2 UV (UV) 5 d
after sensitization and were cultured in the pres-
ence or absence of DNBS for 72 h. Cell proliferation
was measured by [3H]thymidine incorporation (n = 3
mice per group). (D) Reduced DNBS-induced IFN-γ
production in LNs cells from UV-irradiated mice. LN
cells were prepared as above and were cultured
with or without DNBS for 48 h. The amount of IFN-γ
in the culture medium was measured by ELISA (n = 3
mice per group). (E) Increase in Treg cells in LNs
after UV irradiation. LNs were collected from mice
at indicated times after UV irradiation or from control mice without irradiation (No UV), and CD4+Foxp3+ Treg cells in LNs were quantiﬁed by ﬂow cytometry
(n = 3 mice per group). (F) Suppressed UV-induced immunosuppression in Treg-depleted Foxp3hCD2/hCD52 mice. Foxp3hCD2/hCD52 and wild-type mice were
injected i.v. with 0.5 mg of Mabcampath 1 d before irradiation. Ear swelling was measured 24 h after challenge (n = 4 mice per group). Data are repre-
sentative of at least three independent experiments with similar results and are shown as mean ± SEM. *P < 0.05; **P < 0.01.









changes were reversed by treatment with the EP4 antagonist
(Fig. S5). Consistent with such changes, LN cells taken from
EP4 antagonist-treated, UV-irradiated mice exhibited signiﬁ-
cantly increased cell proliferation and IFN-γ production in
response to DNBS compared with LN cells from control ir-
radiated mice (Fig. 2 D and E). These results suggest the
importance of PGE2–EP4 signaling in UV-induced immuno-
suppression. To verify this hypothesis, we examined whether
administration of an EP4 agonist (ONO-AE-1-329) (26) can
restore immunosuppression in irradiated mice treated with
indomethacin. Mice treated with 4 mg kg−1 d−1 indomethacin
added to drinking water from day 0 to day 3 were subjected
to UV irradiation on day 1 and were injected s.c. with different
doses of the EP4 agonist immediately and 12 h after the
UV irradiation (Fig. 3A). We conﬁrmed that this injection of
ONO-AE-1–329 can induce systemic EP4-blocking effects
in mice injected with LPS (Fig. S6). Administration of ONO-
AE-1–329 alone did not affect CHS responses (Fig. 3B).
However, this compound dose-dependently restored the im-
munosuppression in the indomethacin-treated, UV-irradiated
mice (Fig. 3B). This effect was mimicked by CAY10580, an-
other EP4 agonist with a structure different from ONO-AE-1–
329, but not by agonists for DP, EP2, or IP, which, like EP4,
activate Gs protein (16) (Fig. S7). These ﬁndings afﬁrm the
action of PGE2–EP4 signaling in UV-induced systemic immu-
nosuppression.
PGE2–EP4 Signaling Facilitates Increase of Treg Cells in Regional LNs
After UV Irradiation. To explore the mechanism of immunosup-
pressive action of PGE2–EP4 signaling, we collected axillary and
inguinal LNs from UV-irradiated mice 4 d after irradiation and
examined the effect of the EP4 antagonist on the number and
composition of cells in these LNs. TheUV irradiation signiﬁcantly
increased the total number of the LN cells, and the treatment of
the EP4 antagonist did not affect this increase (Fig. 4A). The
numbers of cells in the CD4 (CD4+CD8−), CD8 (CD8+CD4−), B
(B220+), NK (DX5+Thy1.2−), and NKT (DX5+Thy1.2+) cell
population also increased in the peripheral LNs after UV irradi-
ation, but, again, there was no signiﬁcant difference in the cell
number of each of these populations between the mice treated
with the EP4 antagonist and mice treated with the control vehicle
(Fig. S8). However, the increase in Treg cells (deﬁned as
CD4+Foxp3+ cells) in the regional LNs after the irradiation was
signiﬁcantly lower both in number andpercent inmice treatedwith
either the EP4 antagonist or indomethacin than in control mice
treated with vehicle (Fig. 4 B and C and Fig. S9). These results
indicate the involvement of PGE2–EP4 signaling in increase in
Treg cells after UV irradiation.
PGE2–EP4 Signaling Mediates Epidermal RANKL Induction and Induces
Epidermal DCs Expressing DEC205 in UV-Irradiated Mice. Loser et al.
(13) previously reported that UV irradiation up-regulated
RANKL expression in the epidermis and induced DCs expressing
Fig. 2. Reversal of UV-induced immunosuppression by COX inhibition or EP4 receptor antagonism. (A) Effects of indomethacin. Mice were administered 4 mg
kg−1 d−1 of indomethacin (Indo) or vehicle (Veh) in drinking water from day 0 to day 3, and the CHS response was measured 24 h after challenge. (B) Effects of
PG receptor deﬁciency. Mice deﬁcient in DP1, EP1, EP2, EP3, FP, IP, or TP (DP1KO, EP1KO, EP2KO, EP3KO FPKO, IPKO, and TPKO, respectively) and TP-deﬁcient
mice treated with 10 mg kg−1 d−1 of ramatroban (TPKO+Ram) were used with their wild-type counterparts as control. Ear swelling was measured 24 h after
challenge (n = 4 mice per group). (C) Effects of ONO-AE3-208. Mice were administered the indicated doses of an EP4 antagonist, ONO-AE3-208 (EP4ant) or
vehicle (Veh) dissolved in drinking water from day 0 to day 3. Ear swelling was measured 24 h after challenge (n = 4 mice per group). (D and E) Effects of the
EP4 antagonist on LN cell proliferation and IFN-γ production. Mice administered 50 mg kg−1 d−1 ONO-AE3-208 or vehicle from day 0 to day 3 were subjected
to UV or sham irradiation on day 1 and then were sensitized with 0.5% DNFB on day 5. LNs were excised on day 10, and LN cells were subjected to DNBS-
induced cell proliferation (D) and IFN-γ production (E) (n = 3 mice per group). Data are representative of three experiments with similar results and are shown
as mean ± SEM. **P < 0.01; N.S., not signiﬁcant.
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DEC205 there, both of which they suggested might be responsible
for induction of Treg cells in the peripheral lymphoid organs. We
therefore analyzed the effect of the EP4 antagonist on the ex-
pression of RANKL in the skin. Real-time RT-PCR analysis of
the skin exhibited a marked increase in RANKLmRNA after UV
irradiation, and this increase was signiﬁcantly suppressed by
treatment with the EP4 antagonist (Fig. 5A). We also immunos-
tained for RANKL in the skin of control mice and mice treated
with the EP4 antagonist. The UV irradiation markedly enhanced
immunoﬂuorescent signals for RANKL in keratinocytes that were
costained with an antibody to cytokeratin, a marker for keratino-
cytes. Additionally, keratinocytes formed multiple layers after the
irradiation, suggesting that they underwent activation. Treatment
with the EP4 antagonist substantially suppressed RANKL ex-
pression in the epidermis to the level seen in nonirradiated control
mice and preventedmultilayer formation (Fig. 5B).We also found
that treatment with indomethacin elicited the same result as
treatment with the EP4 antagonist, and the addition of the EP4
agonist could restore keratinocyte activation and RANKL pro-
duction after UV irradiation in mice treated with indomethacin
(Fig. 5B). These results indicate that PGE2–EP4 signaling medi-
ates RANKL expression induced by UV irradiation in keratino-
cytes. We next examined the number of DCs expressing DEC205
(CD11c+DEC205+) specialized to induce Foxp3+ Treg cells (15)
in the LNs. We detected a markedly increased number of
CD11c+DEC205+ cells in the peripheral LNs 2 d after UV irra-
diation, and this increase of CD11c+DEC205+ cells was sup-
pressed signiﬁcantly by treatment with the EP4 antagonist (Fig.
5C). Although these results indicate that fewerDEC205+DCs are
present in the LNs to induce Treg with the EP4 antagonism, we
also noted that the total number of CD11c+ DCs in the LNs de-
creasedwith theEP4 antagonist treatment 2 d afterUV irradiation
(Fig. 5C). These results might reﬂect the interference of DC mi-
gration by the EP4 antagonist, as we previously reported (24), and
raised a question whether the EP4 antagonism suppressed in-
duction of CD11c+DEC205+ cells by UV irradiation in situ in the
skin. We therefore isolated epidermal sheet 2 d after UV irradi-
ation and examined the number of CD11c+DEC205+ cells in the
epidermis. UV irradiation signiﬁcantly increased the population
of CD11c+DEC205+ cells in the epidermal cells, and the treat-
ment with the EP4 antagonist suppressed this increase of
CD11c+DEC205+ cells (Fig. 5D). These results clearly show that
the lack of PGE2–EP4 signaling leads to reduced induction of
CD11c+DEC205+ cells in the skin. To verify further that PGE2–
EP4 signalingmediatesUV-induced systemic immunosuppression
by regulating epidermalRANKL,we treatedmice with either anti-
RANKLor the isotype control antibody 2 d beforeUV irradiation.
Anti-RANKL treatment could diminish immunosuppression by
UV irradiation to a degree similar to indomethacin treatment (Fig.
6). There was no additive effect of treatments with indomethacin
and anti-RANKL antibody. Further, treatment with the EP4 ag-
onist did not restore immunosuppression in indomethacin-treated
mice cotreated with anti-RANKL. These results suggest that
RANKL is indispensable for the PGE2–EP4 signaling to mediate
UV-induced systemic immunosuppression. It also is noted that
administration of either anti-RANKL antibody or indomethacin
did not restore the immune response fully to the level observed in
control non–UV-irradiated mice.
Discussion
UV radiation is not only carcinogenic but also suppresses im-
munity. Here, we answered a long-standing question regarding
the role of prostanoids in UV-induced systemic immunosup-
pression by showing that PGE2–EP4 signaling mediates UV-
induced systemic immunosuppression. We showed impairment
of the immunosuppressive effect of UV by EP4 antagonism and
reversal of the indomethacin-induced impairment of immuno-
suppression by EP4 agonism. Notably, treatment with the EP4
agonist alone, without UV irradiation, did not result in immu-
nosuppression (Fig. 3B). Because several immune-modulatory
mediators have been reported to play roles in the UV-induced
systemic immunosuppression (7–10), it is likely that PGE2 acts in
Fig. 3. Restoration of UV-induced immunosuppression in indomethacin-treated mice by administration of an EP4 agonist. (A) The experimental protocol.
Mice treated with indomethacin (Indo) or vehicle (Veh) as in Fig. 2Awere irradiated with 5 kJ/m2 UV on day 1 and were injected s.c. with an EP4 agonist, ONO-
AE1-329 (EP4ago), or vehicle (Veh) immediately and 12 h after the irradiation. The mice then were subjected to CHS induction as in Fig. 1A. (B) Effects of the
EP4 agonist on indomethacin-induced impairment of UV-induced immunosuppression. Mice were treated with vehicle or the indicated doses of ONO-AE1-
329, and the CHS response was measured (n = 4 mice per group). Data are representative of three experiments with similar results and are shown as mean ±
SEM. *P < 0.05; **P < 0.01.
Fig. 4. Selective suppression of the UV irradiation-
induced increase in Treg cells in LNs by EP4 antago-
nism. Mice were administered 50 mg kg−1 d−1 of
ONO-AE3-208 (EP4ant) or vehicle (Veh) from day 0 to
day 3 and were subjected to UV irradiation and sen-
sitization. Draining LNs were excised on day 5, and
the number and composition of Treg cells were ana-
lyzed (n = 4 mice per group). (A) Total cell number of
LNs. (B) The number and percent of CD4+Foxp3+ Treg
cells in LNs. **P < 0.01. (C) Representative dot plot
analysis of CD4+Foxp3+ cells in LNs from the vehicle-
treated UV-irradiated mice and EP4 antagonist-treated
UV-irradiated mice. Data are representative of three
experiments with similar results and are shown as
mean ± SEM.









collaboration with other mediators to induce the immunosup-
pression after UV irradiation. Indeed, we previously showed that
PGs such as PGE2 and PGI2 collaborate with IL-1β and enhance
induction of various cytokines and remodeling factors, including
RANKL, in a model of collagen-induced arthritis (27). Which
mediator collaborates with PGE2 to induce immunosuppression
remains to bedetermined. By examining the cell populations of the
peripheral LNs after UV irradiation, we found that only an in-
crease in the Treg cell population after UV irradiation was sig-
niﬁcantly suppressed by treatment with the EP4 antagonist,
whereas the EP4 antagonist did not affect increases in numbers of
other LN cell populations, including NKT cells, which previously
were reported to mediate systemic immunosuppression after UV
irradiation (11). Using Foxp3hCD2/hCD52 mice, we further showed
that Treg cells play an indispensable role in UV-induced systemic
immunosuppression. We also used anti-RANKL antibody and
showed that RANKL makes a major contribution to this process.
Our results, however, do not exclude an involvement of signaling
molecules other than PGE2 in immunosuppression in a process
independent of PGE2–EP4–RANKL signaling, because the EP4
antagonism did not completely suppress the increment of Treg
cells after UV irradiation, and anti-RANKL antibody did not re-
store ear swelling to the level found in control mice.
Here we identiﬁed PGE2–EP4 signaling as an initiating factor
for RANKL expression in keratinocytes. Classically, PGE2 was
known as an osteolytic factor that functions in osteoblasts down-
stream of proinﬂammatory cytokines such as IL-1β, IL-6, and
TNF-α in induction of osteoclasts from bone marrow precursor
cells. We previously identiﬁed the receptor mediating this action
as EP4 (28). The molecule induced by PGE2 treatment and re-
sponsible for osteoclastogenesis was identiﬁed as RANKL (29).
Thus, our present study has revealed that the identical PGE2–
EP4–RANKL signaling operates in different types of cells with
different consequences, one for osteolysis and the other for
immunomodulation. It also is noted that PGE2–EP4 signaling can
exhibit apparently opposite immunomodulatory actions in differ-
ent situations. We recently used the EAE mouse model and
showed that PGE2–EP4 signaling promotes immune inﬂammation
through Th1 cell differentiation and Th17 cell expansion (30),
whereas our current study showed that the identical signaling
promotes immunosuppression. How such context-dependent dif-
ferences arise should be deﬁned clearly so that the EP4 antagonist
can be used properly and safely in therapeutics in the future. In
addition, UV-induced immunosuppression has been implicated in
nonmelanoma skin cancers caused byUVradiation (1, 12, 31), and
Fig. 5. PGE2–EP4 signaling mediates the
expression of RANKL in keratinocytes and
induces DCs expressing DEC205 in UV irra-
diation. Mice were treated with 50 mg kg−1
d−1 ONO-AE3-208 (EP4ant) or vehicle (Veh)
from day 0 and were subjected to UV or
sham irradiation on the back on day 1. (A)
Effects of EP4 antagonism on UV-induced
expression of RANKL mRNA in the skin. The
back skin was excised 1 d after irradiation,
and Rankl mRNA expression in the skin was
evaluated by quantitative real-time PCR
analysis and is shown in arbitrary expression
units (AU). Rankl expression is normalized
to that of Gapdh (n = 3 mice per group). (B)
Effect of EP4 antagonism and EP4 agonism
on UV-induced increase in RANKL protein in
keratinocytes. For EP4 agonist treatment,
mice were treated with 4 mg kg−1 d−1 in-
domethacin (Indo) from day 0 on, were
subjected to UV irradiation, and were
injected s.c. with 500 μg/kg ONO-AE1-329
(EP4ago), or vehicle immediately and 12 h
after the irradiation. The back skin was ex-
cised 2 d after irradiation and was stained
for RANKL (red) and cytokeratin (green).
Cell nuclei were stained with Hoechst-
33342. (Scale bar, 50 μm.) (C) Effects of EP4
antagonism on the increase of DEC205+ DCs
in LNs after UV irradiation. LNs were col-
lected 2 d after UV irradiation, and the
number of CD11c+ and CD11c+DEC205+ cells
in LNs was analyzed by ﬂow cytometry (n =
4 mice per group). (D) Effects of EP4 an-
tagonism on the UV-induced increase of
DEC205+ DCs in the skin. Epidermal cells were prepared from back skins excised 2 d after irradiation, and CD11c+ cells were isolated by magnetic-activated cell
sorting (MACS). DEC205+ cells in isolated CD11c+ cells were analyzed by ﬂow cytometry (n = 4 mice per group). Data are representative of three experiments
with similar results and are shown as mean ± SEM. *P < 0.05; **P < 0.01.
Fig. 6. RANKL is indispensable for EP4-mediated, UV-induced systemic im-
munosuppression. Mice were injected s.c. with 100 μg of either anti-RANKL
or isotype control antibody (Control) 2 d before UV irradiation. In-
domethacin (Indo), 4 mg kg−1 d−1, and ONO-AE1-329 (EP4ago), 500 μg/kg,
were administered as in Fig. 3A. The CHS response was measured (n = 4 mice
per group). Data are representative of two experiments with similar results
and are shown as mean ± SEM. *P < 0.05; **P < 0.01.
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the incidence of nonmelanoma skin cancers was lower in subjects
receiving a selective COX-2 inhibitor, celecoxib, than in subjects
receiving placebo (32). We hope that the action of PGE2–EP4
signaling we have described here is exploited in various clinical
settings, including this malignancy.
Materials and Methods
Animals. Mice lacking each type or subtype of PG receptor individually were
generated and backcrossed more than 10 times onto C57BL/6 background as
described previously (23). Foxp3hCD2/hCD52 mice with C57BL/6 background
were generated as described (22). Female mice of each genotype were used
at age 8–10 wk. Wild-type C57BL/6CrSlc mice (Japan SLC) were used as
controls. All mice were maintained on a 12-h/12-h light/dark cycle under
speciﬁc pathogen-free conditions. All experimental procedures were in ac-
cordance with the National Institutes of Health Guide for the Care and Use
of Laboratory Animals and were approved by the Committee on Animal
Research of Kyoto University Faculty of Medicine.
UVB Irradiation and CHS. A bank of sunlamps emitting 280–360 nm with
a peak emission at 313 nm (FL 20SE; Toshiba) arranged in parallel was used
as a source of UVB. The irradiance, measured by an UVR-305/365D radiom-
eter (Tokyo Kogaku), was 5 J/m2 s−1 at a distance of 40 cm. On day 0, back fur
was shaved with electric clippers. On day 1, mice were exposed to 5 kJ/m2 of
UVB on the shaved back with their ears and eyes protected. They were
sensitized by applying 25 μL of 0.5% (wt/vol) DNFB (Sigma) in acetone/olive
oil (4/1, vol/vol) on the shaved abdomen on day 5. Then, on day 10, the mice
were challenged by application of 20 μL of 0.2% DNFB to the dorsal and
ventral surfaces of both ears. The ear thickness of each mouse was measured
before and 24 h after elicitation at a predetermined site with a micrometer,
and the difference was expressed as ear swelling.
For drug treatment, 4 mg kg−1 d−1 of indomethacin (Nacalai) or 10–100
mg kg−1 d−1 of ONO-AE-3–208 in drinking water was given ad libitum from
day 0 to day 3; 5 mg kg−1 of Ramatroban (Tocris) was injected s.c. every 12 h
to TP-deﬁcient mice from day 0 to day 3; and 5–500 μg/kg of ONO-AE-1–329
in 0.9% saline was injected s.c. immediately and 12 h after UV irradiation.
For anti-RANKL treatment, mice were injected s.c. with 100 μg of anti-
mouse RANKL (Oriental Yeast) 2 d before UV irradiation. The same amount
of rat IgG2a antibody (eBioscience) was used as a control.
Lymphocyte Culture. Single-cell suspensions were prepared from inguinal and
axillary LNs of mice 5 d after sensitization with 0.5% DNFB. The cells were
cultured at 5 × 105 cells per well in a 96-well plate in 200 μL of RPMI-1640
containing 10% FBS with or without 100 μg/mL DNBS (Sigma) for 3 d and
were pulsed with 0.5 μCi [3H]thymidine for the last 24 h of culture. The acid-
insoluble radioactivity was determined by liquid scintillation counting. For
measurement of cytokine production, the cells were cultured for 48 h, and
the culture supernatants were collected. IFN-γ in the supernatants was
measured using an IFN-γ ELISA kit (Endogen).
Immunoﬂuorescence. Immunostaining was performed on 10-μm cryostat sec-
tions of mouse back skin embedded in optimal cutting temperature (OCT)
compound. Tissue sections were ﬁxed in precooled acetone for 10 min. Anti-
RANKL and anti-cytokeratin antibodies were used as primary antibodies.
Biotinylated anti-rat IgG (Vector) and Alexa Fluor 488 anti-mouse IgG (Invi-
trogen) were used as secondary antibodies. The RANKL signal was ampliﬁed
using the tyramide signal ampliﬁcation (TSA) Plus Cyanine-3 System (Perkin-
Elmer) according to the manufacturer’s protocol. Cell nuclei were stained us-
ing Hoechst-33342 (Invitrogen) according to the manufacturer’s instruction.
Statistical Analysis. Data were analyzed by Student’s t test, and differ-
ences were considered signiﬁcant at P < 0.05. All bar graphs represent the
mean ± SEM.
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